Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373984 | 1.00 | CISD1 (0.40) | CISD1CSNK2A2CSNK2A1ALOX5GPR84 | |
| SCHEMBL3372738 | 0.84 | CISD1 (0.36) | CISD1CSNK2A2CSNK2A1 | |
| SCHEMBL13069005 | 0.84 | CISD1 (0.36) | CISD1CSNK2A2CSNK2A1 | |
| SCHEMBL3372704 | 0.84 | CISD1 (0.36) | CISD1CSNK2A2CSNK2A1 | |
| SCHEMBL5570153 | 0.82 | CISD1 (0.40) | CISD1CSNK2A2CSNK2A1GPR84MAPT | |
| SCHEMBL5570152 | 0.82 | CISD1 (0.40) | CISD1CSNK2A2CSNK2A1GPR84MAPT | |
| SCHEMBL3372531 | 0.81 | CISD1 (0.37) | CISD1 | |
| SCHEMBL3372536 | 0.81 | CISD1 (0.37) | CISD1 | |
| SCHEMBL3372390 | 0.81 | CISD1 (0.34) | CISD1 | |
| SCHEMBL3374703 | 0.81 | CISD1 (0.34) | CISD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101155808-B | Substituted 1,5-naphthyridine azolidinones as cdk inhibitors | HOFFMANN LA ROCHE | 2011-08-31 | — | — | CN | claimed |
| EP-1869036-B1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-11-03 | — | — | EP | claimed |
| CN-101155808-A | Substituted 1,5-naphthyridine azolidinones as cdk inhibitors | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | CN | claimed |
| EP-1869036-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-12-26 | — | — | EP | claimed |
| US-7304074-B2 | Substituted 1,5-naphthyridine azolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-12-04 | — | — | US | claimed |
| WO-2006106046-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | claimed |
| US-20060223843-A1 | Substituted 1,5-naphthyridine azolinones | LIU JIN-JUN | 2006-10-05 | — | — | US | claimed |
| CN-101155808-B | Substituted 1,5-naphthyridine azolidinones as cdk inhibitors | HOFFMANN LA ROCHE | 2011-08-31 | — | — | CN | disclosed |
| EP-1869036-B1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-11-03 | — | — | EP | disclosed |
| CN-101155808-A | Substituted 1,5-naphthyridine azolidinones as cdk inhibitors | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | CN | disclosed |
| EP-1869036-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-12-26 | — | — | EP | disclosed |
| US-7304074-B2 | Substituted 1,5-naphthyridine azolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-12-04 | — | — | US | disclosed |
| WO-2006106046-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | disclosed |
| US-20060223843-A1 | Substituted 1,5-naphthyridine azolinones | LIU JIN-JUN | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223843-A1 | Substituted 1,5-naphthyridine azolinones | CDK4, CDK1, CDK14 | CISD1 1560/4885CSNK2A2 268/4885CSNK2A1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.